Our History

ReGen (Therapeutics Plc) was formed in February 1998 to develop Colostrinin™, a proline-rich polypeptide complex derived from mammalian colostrum. The complex and the peptides within it are viewed as having potential utility in neurodegenerative illnesses such as Alzheimer’s disease, Parkinson’s Disease, Multiple Sclerosis and Amyotrophic Lateral Sclerosis.

The Company’s shares were admitted to trading on the London OFEX market in December 1998. ReGen floated on the Alternative Investment Market of the London Stock Exchange in March 2000. As of the 18th February 2011 ReGen became a private limited company on the Jenkins share-trading facility: http://www.jpjenkins.ltd.uk/.